The FDA accepted GSK's New Drug Application for bepirovirsen for priority review in adults with chronic hepatitis B. Priority review signals an accelerated regulatory timeline and is a positive development for Ionis Pharmaceuticals' partner program. The news is constructive for the companies involved, though it is still an approval step rather than a final decision.
The FDA accepted GSK's New Drug Application for bepirovirsen for priority review in adults with chronic hepatitis B. Priority review signals an accelerated regulatory timeline and is a positive development for Ionis Pharmaceuticals' partner program. The news is constructive for the companies involved, though it is still an approval step rather than a final decision.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
